	Approved for use through 07/31/2006	OMB 0651-003
	U.S. Patent and Trademark Office; U.S. DEPARTMENT	OF COMMERC
Under the Paperwork Reduction Act of 1565.	no persons are required to respond to a collection of information unless it contains a valid DM	R control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10790932	
	Filing Date		2004-03-02	
	First Named Inventor North		hiko Tanaka	
	Art Unit		3618	
	Examiner Name	Vaug	hri Coolman	
	Attorney Docket Numb	er	FY.51036US1A	

	_			U.S.	PATENTS	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					
lf you wisi	n to a	dd additional U.S. Paten	t citatio	n information p	lease click the Add button.	
			U.S.P	ATENT APPL	CATION PUBLICATIONS	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1 .	20040216942		2004-11-04	Takenaka et al.	
	2	20050103553		2005-05-19	Korenjak et al.	
	3	20050109554		2005-05-26	lshikawa et al.	
	4	20050126842		2005-06-16	Rasidescu et al.	
	5	20050150706		2005-07-14	Eguchi et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1,99)

plication Number		10790932				
ing Date		2004-03-02				
rst Named Inventor	Nonih	Norihiko Tanaka				
t Unit		3618				
raminer Name	Vaug	hn Coolman				
		D/F4000HD44				

	6	20050230209		2005-10-20	Duignan			
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication citatio	n information	please click the Add	button.	
				FOREIGN PA	TENT DOCUM	MENTS		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patentee Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	тя
	1							
Manager series		dd addistanat Panatan D	-tt-		1-6		1.46	

ent Document citation information please click the Add button

ION-PA	IENI	LITERA	IURE	DOCUMENTS	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city anotic rountly where publisher, div anotic rountly where publisher, div	Ţs
	1	·	_

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature Date Considered

F

Α

Ε

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Nati Codes of USPTO Petert Documents at ImmuNESTO_COLV or NRFP 601.04. * Enter office that Issued the document, by the law-inter of NVPO-Standard ST3.8.* * For Supersee petert of counters, the indication of the year of the register or many personals has said insurance of the peter document.

* Aircl of Coursent by this appropriate symbols as indicated on the document under WEPO Standard ST 16 if possible, * Applicant is to place a check mark here if Emploit Insurance insurance in address the supersonal peter of the peter of the

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1,99)

Application Number		10790932	
Filing Date		2004-03-02	
First Named Inventor	Norihiko Tanaka		
Art Unit		3618	
Examiner Name	Vaughn Coolman		
Attorney Docket Number		FY.51036US1A	

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication, from a foreign partent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of Information contained in the Information disclosure statement was cited in a communication from a foreign potent refice in a counterpart freeign application, and, to the investedge of the person spling the conflictation and the information disclosure statement was known to any individual designated in 3" CPR 1.56(c) more than these months prior to the filling of the information disclosure

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1,97 and 1.98 to make the appropriate selection(s):

None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature Date (YYYY-MM-DD) 2007 - DV - ID

Name/Print William H. Shreve Registration Number 35.676

This collection of Information is required by 37 CFR 197 and 19.8. The information is required to obtain or retain a benefit by CFR public which it is follied up the y LEPFO to process) an application. Confidentiality is governed by 59 U.S. C. 122 and 57 FR. 1.4. This collection is estimated to take 1 hour to complete, including agathering, preparing and submitting the completed application from the USFFO. Time will very depending upon the including agathering, preparing and submitting the completed required to complete the submitted of the process of the Cited information Officer U.S. required to complete this form and/or appealsons for reducing this burdon, should be sent to the Cited information Officer U.S. required to complete this form and/or appealsons for reducing this burdon, should be sent to the Cited information Officer U.S. required to complete the Cited information Officer U.S. required to the Cited information of the Cited information Officer U.S. required to the Cited information of the Cited

VA 22313-1450

Privacy Act Statement

The Privacy Act of 1974 (P. L. 35-375) regulars that you be given certain information in connection with your submission of the attached form resident due a patient application or patient. Accordingly, pursuant of the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is SULS.C. 2(b)(2); (2) Junishing of the Information solidate is collutary, and (3) the priprical purpose for which the Information is used by the U.S. Patient and Tradermack Office is to be process and/or examine your dutinisation related to a patient application or patient. If you do not format the examined to the patient application or patient. If you claim-lated in the ministry of processings or eta-advolument of the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neoditations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
 request involving an individual, to whom the record pertains, when the individual has requested assistance from the
 Member with reserved to the sublicit matter of the record
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records mey be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designes, clufting an inspection of eroods conducted by SSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2908. Such disclosure shall be made in accordance with the GSA regulations governing impection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about Individuals.
- 5. A record from this system of records may be disclosed, as a routine use, b the public after either publication of the application prurate to 3.8 U.S. C. 115. TextDay or issusmor on a paster pursuant to 3.8 U.S. C. 115. TextDay or issusmor on a paster pursuant to 3.8 U.S. C. 115. TextDay or any be disclosed, adolpts to the inflations of 37 CFR 1.14, as a routine use, to the public if the record week fiscill in an application provided to the public that the record week fiscillar in a replication on an application on an application on an application on any position in part of the record of the
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.